Fuji Pharma Co Ltd
TSE:4554
Fuji Pharma Co Ltd
Net Income (Common)
Fuji Pharma Co Ltd
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Fuji Pharma Co Ltd
TSE:4554
|
Net Income (Common)
¥5.1B
|
CAGR 3-Years
24%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Net Income (Common)
¥178.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
2%
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Net Income (Common)
¥186.1B
|
CAGR 3-Years
38%
|
CAGR 5-Years
23%
|
CAGR 10-Years
5%
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Net Income (Common)
¥121.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-4%
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Net Income (Common)
¥325.5B
|
CAGR 3-Years
15%
|
CAGR 5-Years
29%
|
CAGR 10-Years
20%
|
|
Astellas Pharma Inc
TSE:4503
|
Net Income (Common)
¥37.3B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-9%
|
See Also
What is Fuji Pharma Co Ltd's Net Income (Common)?
Net Income (Common)
5.1B
JPY
Based on the financial report for Dec 31, 2023, Fuji Pharma Co Ltd's Net Income (Common) amounts to 5.1B JPY.
What is Fuji Pharma Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
10%
Over the last year, the Net Income (Common) growth was 88%. The average annual Net Income (Common) growth rates for Fuji Pharma Co Ltd have been 24% over the past three years , 10% over the past five years , and 10% over the past ten years .